Surgeons eye off-label dermal filler aimed at HIV patients
This article was originally published in Clinica
Executive Summary
To some critics it's a backdoor technique. But there are ways for potential blockbuster products to win FDA approval on only limited clinical data if the sponsors file a submission for a very narrow, but important, indication.